Crescent Biopharma reports about $171.6 million in cash as of June 30, 2026

Crescent Biopharma, Inc. filed a Form 8-K dated July 14, 2026 disclosing preliminary financial information for the quarter ended June 30, 2026. As of June 30, 2026, the Company estimates that its cash and cash equivalents were approximately $171.6 million.¹

The company cautioned that this figure is not final. The cash figure is based on unaudited preliminary information and management estimates, and does not represent a complete statement of the company's financial results for the quarter, pending completion of its financial closing procedures.¹ Crescent's management prepared the data and takes responsibility for it, as the preliminary financial data included in the report has been prepared by, and is the responsibility of, the company's management.¹

The company's outside auditor has not yet reviewed the numbers. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, or applied agreed-upon procedures to the preliminary financial data, and therefore does not express an opinion or any other form of assurance on it.¹

Crescent flagged that final results could differ from these estimates. The company said actual results for the second quarter or full year of 2026 may differ materially from the preliminary estimates due to changes in assumptions, the completion of internal control reviews, other quarter-end and year-end procedures, and other risks described in its prior SEC filings, including its 2025 annual report and its first-quarter 2026 quarterly report.¹

The filing did not include additional pipeline, clinical, or regulatory updates. It was signed by Chief Executive Officer Joshua Brumm.